4basebio AG: 4basebio reports on results of Annual General Meeting 2020
DGAP-News: 4basebio AG
/ Key word(s): AGM/EGM
Heidelberg, Germany and Cambridge, UK, 17 June 2020 - 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) announces the results of the Annual General Meeting (AGM) held today on June 17, 2020. The shareholders approved all resolutions proposed by the Management Board and Supervisory Board, published in the Federal Gazette on May 8, 2020, with a large majority.
Dr Heikki Lanckriet, CEO of 4basebio AG, said: "We would like to thank our shareholders for their trust and support in the reorientation of our company towards the field of innovative DNA production, a promising future market. We are also pleased that, following the successful share buyback program in April of this year, we have now received approval for a further buyback if this is appropriate."
The Company made use of the option provided by the German legislator in view of the coronavirus pandemic to conduct the ordinary AGM as a virtual meeting without the physical presence of shareholders or their proxies. Via a password-protected online platform, registered shareholders could exercise their voting rights before and during the AGM and submit questions until two days prior to the event. The AGM could be followed online in sound and vision.
Further information on the Annual General Meeting including the detailed voting results and the Management Board presentation can be found on the AGM 2020 page at: https://investors.4basebio.com/annual-general-meeting/
About 4base bio:
MC Services AG (Investor Relations and International Media Relations)
### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###
17.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Waldhofer Str. 102|
|Phone:||+49 (0) 6221 3540 125|
|Fax:||+49 (0) 6221 3540 127|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1072693|
|End of News||DGAP News Service|